United Therapeutics UTHR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $2.9M-62.8% | $7.8M-19.6% | $9.7M+49.2% | $6.5M+8.3% | $6M+27.7% | |
| Nebulized Tyvaso | $127.2M+1.2% | $125.7M-11.4% | $141.8M-8.2% | $154.4M-5.7% | $163.8M+14.8% | |
| Orenitram | $135.6M+11.9% | $121.2M-7.6% | $131.1M+5.8% | $123.9M+2.7% | $120.7M+12.0% | |
| Remodulin | $126.6M-1.1% | $128M+1.7% | $125.9M-6.5% | $134.7M-2.5% | $138.2M+2.8% | |
| Tyvaso DPI | $330.3M-2.5% | $338.6M+0.7% | $336.2M+6.7% | $315.2M+4.2% | $302.5M+10.7% | |
| Unituxin | $53.6M-14.0% | $62.3M+30.1% | $47.9M-18.0% | $58.4M+0.3% | $58.2M-13.8% | |
| Total revenues by Geography | ||||||
| ROW | $37.3M-0.3% | $37.4M+51.4% | $24.7M-36.3% | $38.8M-13.4% | $44.8M+48.3% | |
| U.S. | $744.2M-1.1% | $752.8M-2.8% | $774.8M+2.0% | $759.8M+1.4% | $749.6M+6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
